Company intelligence / Profile preview
TeGenero AG
Würzburg, Bavaria, Germany
- Ownership
- Private
- Development stage
- Other
01
Overview
TeGenero AG was a German biotech spin-out from the University of Würzburg that developed TGN1412, a humanized monoclonal antibody targeting CD28 as an immunomodulator. In March 2006, its first-in-human Phase I trial resulted in life-threatening cytokine storm reactions among all volunteers. The incident led to global scrutiny of early-phase clinical trials and caused the company's bankruptcy within months. The drug's rights were later acquired by another entity and renamed TAB08 for further development elsewhere.
- Therapeutic areas
- OncologyImmunology
- Modalities
- monoclonal antibodies (mAbs)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Manufacturing partner for TGN1412 was Boehringer Ingelheim during initial development.
Beyond the preview
Go deeper on TeGenero AG.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TeGenero AG.